Newsroom
Follow the latest developments in migrasome science, technology platforms, product development, partnerships and scientific exchange at Migrasome Therapeutics.
12 stories
Selected among the Top 10 medical-device projects: the company's migrasome-based diagnostics and instrumentation platform.
Read story
More than 30 experts shared advances in migrasome biology at the 2025 International Migrasome Conference. Migrasome Therapeutics presented its 3R translation strategy and a research-tool portfolio spanning visualization, isolation, purification, detection and characterization.
Read story
China Science Daily profiled the company’s entrepreneurial and translational progress, including its engineered migrasome delivery system, research kits, tumor-immunology platform and support from both public and private funding.
Read story
Tsinghua x-lab profiled the company’s engineered migrasome delivery system, multidisciplinary founding team and the step-by-step construction of its production, purification and quality-control platform.
Read story
The team’s migrasome-biology-based drug-development project placed first among 168 teams and received the competition’s highest honor, the Meiling Gold Award.
Read story
At the first International Migrasome Conference in Shenzhen, the company presented work on migrasome cargo loading and delivery, moderated a roundtable on medical applications and previewed a migrasome isolation and purification kit.
Read storyProfessor Li Yu discussed the original science behind migrasomes, the company’s Read–Rectify–Rebuild strategy, its engineered delivery platform and the importance of open collaboration.
Read story
The Angel+ equity financing will support the company’s migrasome-based drug-delivery platform, migrasome-related therapeutics and diagnostics, as well as continued development of R&D, manufacturing and quality capabilities.
Read story
The company’s multifunctional migrasome-based delivery platform advanced to the final of the 6th Zhongguancun International Frontier Technology Competition and received a Top 10 award in the biopharmaceutical category.
Read story
As a member of the Roche Accelerator in China, Migrasome Therapeutics will draw on scientific, industry and operational resources to advance its engineered migrasome delivery platform and innovative programs in immunology, oncology and other areas.
Read story
Only months after its founding, Migrasome Therapeutics was selected among the Top 10 biopharmaceutical projects for its multifunctional migrasome-based delivery platform.
Read story
